Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2022-03-17 00:00:00 ET · period of report 2022-03-15 · accession 0001209191-22-019815 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-17 | 2022-03-15 | DFTX | Barrow Robert | CEO, Dir | F - Tax | $1.00 | -12.6K | 2.21M | -0.6% | -$12.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Subordinate Voting Shares | 2022-03-15 | F | D | 12,612 | $1.00 | 2,213,367 | D | — | — | (F2) The closing price of our Subordinate Voting Shares as of March 15, 2022 on the NEO was $1.28 Canadian Dollars. This represents the price in United States Dollars. |